News

Tsu Shan Chambers, optometrist and filmmaker, blends clinical insight and storytelling to highlight preventable vision loss, retinitis pigmentosa, and the power of ability over disability in her socially conscious film.

Catch up on this week's highlights in retina.

To celebrate Ophthalmology Times' 50th anniversary, we asked leading experts what the practice would look like today had optical coherence tomography (OCT), one of the biggest innovations in the field, never been invented.

Clinicians discuss how the treatment compares with epi-off cross-linking, what may shape adoption, and how patient outcomes could improve.

Marguerite B. McDonald, MD, FACS, reflects on a first-year residency case that taught her the importance of trusting her instincts and advocating for patient safety.

Dr. James Chelnis explores innovative energy-based technologies in aesthetic facial surgery, emphasizing safety, personalized treatments, and future advancements in patient care.

Ophthalmologists discuss topography-guided techniques, long-term corneal health, and emerging technologies set to transform refractive surgery.

Specialists discuss diagnostic technologies, treatment strategies, and research that are improving outcomes for young patients

Deborah A. Ferrington, PhD, highlights how breakthroughs in imaging, AI, and stem cell research are reshaping ophthalmology.

To celebrate Ophthalmology Times' 50th anniversary, we asked leading experts what the practice would look like today had optical coherence tomography (OCT), one of the biggest innovations in the field, never been invented.

Deborah Ristvedt, DO, recalls a retinal detachment repair that took an unexpected turn, teaching lasting lessons in patient awareness and surgical presence.

Emerging devices, wearable technology, and home-monitoring tools are reshaping how clinicians diagnose, treat, and manage patients.

NYRVANA is the first-in-human trial and is an open-label, multicenter, dose-escalation study investigating the safety, tolerability, and preliminary efficacy of a single intravitreal injection of SPVN20 over 6 months.

Regeneron faces another FDA setback for Eylea HD due to manufacturing issues, but plans for new facilities signal future production improvements.

This acquisition will include Adverum’s lead candidate, Ixo-vec, a gene therapy treatment for wet AMD.

The results presented at 2025 European Society of Medical Oncology meeting support neoadjuvant darovasertib as a potential treatment to delay or prevent progression of the disease.

Emerging anti-VEGF agents offer enhanced durability and anatomic outcomes in retinal disease.

SPVN20 is a gene-agnostic, intravitreal AAV-based gene therapy that targets dormant cones to restore vision, according to SparingVision

A mutation-agnostic gene therapy approach offers new possibilities for patients, especially those with inherited retinal diseases

To celebrate Ophthalmology Times' 50th anniversary, we asked leading experts what the practice would look like today had optical coherence tomography (OCT), one of the biggest innovations in the field, never been invented.

Peter J. McDonnell, MD, reflects on his early experience managing bullous keratopathy with penetrating keratoplasty and how advances like DMEK have transformed outcomes across corneal, refractive, and cataract surgery.

Regeneron faces another FDA setback for Eylea HD due to manufacturing issues, but plans for new facilities signal future production improvements.

The satellite of the US-based University of Miami Health System will offer a “full spectrum of ophthalmic services” in the United Arab Emirates

Surgeons weigh in on emerging surgical technologies, premium lens trends, and strategies to optimize patient satisfaction and safety.

Retina specialists share their perspectives on evolving anti-VEGF therapy, pipeline treatments, and strategies to enhance patient outcomes.

Topcon Healthcare enhances its AI capabilities by acquiring Toku, Inc., aiming to revolutionize eye care with advanced predictive health insights.

From MIGS integration to remote monitoring and next-generation therapeutics, glaucoma specialists explore how new approaches are redefining patient outcomes.